Published online Apr 30, 2012.
https://doi.org/10.5534/kja.2012.30.1.13
Hormone Replacement Therapy in Female Sexual Dysfunction
Abstract
Female sexual function is highly complex and deeply influenced by hormonal and non-hormonal factors. As sexual dysfunction becomes a common and important problem for women of all ages with related quality of life issues, we need to understand more about the effect of sex steroid hormones in female sexual function. However, there are limited data about the correlation between the value of sex steroid hormones- testosterone, in particular-and female sexual function. In a certain type of female sexual dysfunction (FSD), hypoactive sexual desire disorder, for example, there is evidence that treatment with androgens or with estrogens is effective. To widen the therapeutic options of hormone replacement therapy in FSD, further research is needed as to the benefits and risks of hormonal treatments in both pre- and post-menopausal women. Although important unanswered questions still exist in hormonal treatment of FSD, new therapeutic strategies are being studied and many ongoing clinical trials are expecting favorable results leading to more successful treatment of FSD.
Fig. 1
Schematic diagram of sex steroidogenesis from cholesterol.
Table 1
Testosterone currently available in Korea*
References
-
Woodis CB, McLendon AN, Muzyk AJ. Testosterone supplementation for hypoactive sexual desire disorder in women. Pharmacotherapy 2012;32:38–53.
-
-
Trocóniz IF, Boland K, Staab A. Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteers. Pharm Res. 2012[Epub ahead of print].
-
-
A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety and efficacy of Lybrido in the domestic setting in healthy female subjects with hypoactive sexual desire disorder and low sensitivity for sexual cues [Internet].
-
-
Nathan SG. When do we say a woman's sexuality is dysfunctional?. In: Levine SB, Risen CB, Althof SE, editors. Handbook of clinical sexuality for mental health professionals. New York: Brunner-Routledge; 2003. pp. 95-110.
-
-
van Thiel SW, Romijn JA, Pereira AM, Biermasz NR, Roelfsema F, van Hemert A, et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. J Clin Endocrinol Metab 2005;90:3295–3303.
-
-
Park K, Kim MK, Kim KW, Ahn KY, Lee SE, Ryu SB. Effect of delayed estrogen replacement on clitoral corpus cavernosal blood flow and histologic composition in rabbit. Korean J Urol 2004;45:268–273.
-
-
Kim JY, Cho JC, Lim SH, Jeong SM, Rhyu CH, Kim JD. Assessment about quality of life in menopausal women with hormone replacement therapy. Korean J Obstet Gynecol 1998;41:2429–2435.
-
-
Jun JH, Yoon H. Effect of menopause on the expression of androgen receptors in human vagina. Korean J Androl 2004;22:24–30.
-
-
Nathorst-Böös J, von Schoultz B. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest 1992;34:97–101.
-
-
Adashi EY. The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fertil Steril 1994;62:20–27.
-
-
Dören M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554–559.
-
-
North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005;12:496–511.
-